Cogent Biosciences (COGT) Cash & Equivalents (2017 - 2026)

Cogent Biosciences' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $241.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 91.43% year-over-year to $241.2 million; the TTM figure through Mar 2026 stood at $241.2 million (up 91.43% YoY), while the FY2025 annual figure was $312.0 million, up 217.84% from the prior year.
• Cash & Equivalents was $241.2 million for Q1 2026 at Cogent Biosciences, down from $312.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $325.6 million in Q2 2022 to a low of $53.2 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $161.4 million across 5 years, with a median of $139.9 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents plunged 61.95% in 2023, then soared 217.84% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $139.9 million in 2022, then slumped by 61.95% to $53.2 million in 2023, then jumped by 84.42% to $98.2 million in 2024, then jumped by 217.84% to $312.0 million in 2025, then declined by 22.69% to $241.2 million in 2026.
• The last three Cash & Equivalents figures came in at $241.2 million (Q1 2026), $312.0 million (Q4 2025), and $125.3 million (Q3 2025), per Business Quant data.